Mark J. Ratain to Regression Analysis
This is a "connection" page, showing publications Mark J. Ratain has written about Regression Analysis.
Connection Strength
0.464
-
Bootstrap validation of pharmacodynamic models defined via stepwise linear regression. Clin Pharmacol Ther. 1994 Aug; 56(2):217-22.
Score: 0.108
-
A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenet Genomics. 2010 Oct; 20(10):638-41.
Score: 0.083
-
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9. Eur J Cancer. 2009 Jul; 45(11):1904-8.
Score: 0.075
-
Limited sampling model for area under the concentration time curve of total topotecan. Clin Cancer Res. 1996 Jan; 2(1):43-6.
Score: 0.030
-
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol. 1995 Mar; 13(3):741-7.
Score: 0.028
-
Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions. Cancer Chemother Pharmacol. 1993; 33(1):1-9.
Score: 0.024
-
Modeling interpatient pharmacodynamic variability of etoposide. J Natl Cancer Inst. 1991 Nov 06; 83(21):1560-4.
Score: 0.022
-
Limited sampling models for doxorubicin pharmacokinetics. J Clin Oncol. 1991 May; 9(5):871-6.
Score: 0.021
-
Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics. 2008 Aug; 18(8):683-97.
Score: 0.018
-
Limited sampling model for vinblastine pharmacokinetics. Cancer Treat Rep. 1987 Oct; 71(10):935-9.
Score: 0.017
-
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol. 2007 Jan; 47(1):78-86.
Score: 0.016
-
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer. J Clin Oncol. 1998 Jun; 16(6):2032-7.
Score: 0.009
-
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). Clin Cancer Res. 1997 May; 3(5):719-25.
Score: 0.008
-
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1993 Feb; 11(2):360-8.
Score: 0.006